Supira Medical

What Supira Medical does

Supira Medical, Inc. is a clinical-stage medical device company headquartered in Los Gatos, California, developing the Supira System, a next-generation percutaneous ventricular assist device (pVAD) for temporary mechanical circulatory support. The device is designed around a 10 French low-profile architecture that delivers high continuous flow and incorporates multiple integrated sensors for real-time aortic and ventricular pressure monitoring, intended to reduce the vascular complications associated with larger existing pVADs while enabling patient mobility through percutaneous axillary access. The Supira System is being developed as a single device platform targeting two primary indications: hemodynamic support during high-risk percutaneous coronary intervention (HRPCI) and treatment of cardiogenic shock.

The company is currently pre-commercial, with the Supira System designated as an investigational device not approved for sale in the U.S. or anywhere in the world. Clinical development has progressed from first-in-human studies initiated in Paraguay in September 2022, through a U.S. Early Feasibility Study (SUPPORT I, 15 patients across 4 sites, enrollment completed by March 2025), to FDA approval in April 2026 of the SUPPORT II Pivotal Trial, which is designed to enroll up to 385 patients across up to 40 U.S. sites in support of a future PMA submission. The company has treated 99 patients cumulatively as of April 2026 across its clinical programs.

Commercially, Supira Medical plans to generate revenue through direct sales of the Supira System to U.S. hospitals and interventional cardiology centers upon regulatory approval, with enterprise sales targeting cath labs performing high-risk PCI and treating cardiogenic shock patients. The company has raised approximately $225 million across five financing rounds (Series B through E), with the most recent $120M Series E in March 2025 led by Novo Holdings and Qatar Investment Authority. Supira operates as a portfolio company of Shifamed, LLC, a medical innovation hub founded by Amr Salahieh, and is led by President and CEO Dr. Nitin Salunke.

Name

Supira Medical

Legal name

Supira Medical, Inc.

Website

https://supiramedical.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Percutaneous Ventricular Assist Devices (Mechanical Circulatory Support)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Percutaneous ventricular assist device
• Mechanical circulatory support
• High-risk PCI devices
• Cardiogenic shock treatment
• Interventional cardiology devices

Headquarters

HQ city

Los Gatos

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Medical Device Sales: Supira Medical is a clinical-stage company developing a percutaneous ventricular assist device. The Supira System is currently an investigational device not approved for sale in the U.S. or anywhere in the world. Revenue will be generated through device sales to hospitals and medical centers upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Supira Medical develops the Supira System, a next-generation percutaneous ventricular assist device (pVAD) featuring a 10 French low-profile, high continuous flow design with integrated real-time pressure sensors. It is engineered to provide temporary mechanical circulatory support for patients undergoing high-risk percutaneous coronary interventions (HRPCI) and for patients experiencing cardiogenic shock. The product is currently investigational and not approved for sale in any market.

Product overview

Supira Medical is a clinical-stage company developing a single unified product platform: the Supira System, a next-generation percutaneous ventricular assist device (pVAD). The Supira System is a low-profile (10F), high-flow mechanical circulatory support device designed for temporary hemodynamic support during high-risk percutaneous coronary interventions (HRPCI) and for patients experiencing cardiogenic shock. The system features integrated sensors for real-time aortic and ventricular pressure monitoring. The company is currently conducting clinical studies (SUPPORT I Early Feasibility Study and SUPPORT II Pivotal Trial) to support FDA PMA approval for U.S. market entry. The Supira System is an investigational device and is not approved for sale in the U.S. or anywhere in the world.

Differentiator

Problem solved

Functional benefit

Brands

• Supira System: Next-generation percutaneous ventricular assist device (pVAD) designed for high-risk PCI and cardiogenic shock patients with a novel low profile, high continuous flow design featuring 10F profile and real-time pressure sensors.

Products and services

• Supira System Next-generation percutaneous ventricular assist device (pVAD) featuring a 10 French low-profile, high continuous flow design with integrated real-time aortic and ventricular pressure sensors. Designed to provide full hemodynamic support during high-risk percutaneous coronary interventions (HRPCI) and for cardiogenic shock patients via a single device platform. Intended for use by interventional cardiologists in hospital cath labs and cardiac care settings. The Supira System is currently an investigational device and is not approved for sale in the U.S. or anywhere in the world.

Quantifiable outcome

• 99 patients treated with the Supira System as of April 2026
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• D. Keith GrossmancoreOthers · 8 April 2026Appointed to Supira Medical's Board of Directors in April 2026. Brings 40 years of leadership experience in medical technology industry, including foundational role in mechanical circulatory support space.
• Dr. Christopher ShencoreOthers · 26 March 2025Partner at Novo Holdings US, joined Supira's Board of Directors as part of the Series E financing.
• ShifamedflagshipStrategic or Co-development Partner · 26 March 2025Supira Medical is a portfolio company of Shifamed, a medical innovation hub founded by serial entrepreneur Amr Salahieh. Shifamed provides development support and resources for portfolio companies.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Abiomed (Johnson & Johnson MedTech): Abiomed's Impella is the dominant and most established percutaneous ventricular assist device used for HRPCI and cardiogenic shock — Supira's direct head-to-head competitor in cath-lab mechanical circulatory support.
• Magenta Medical: Israel-based developer of a low-profile, high-flow transcatheter ventricular assist device aimed at the same HRPCI/cardiogenic shock indications; the closest emerging direct competitor to Supira's design philosophy.
• CardioBridge GmbH: German developer of the Reitan Catheter Pump, a percutaneous mechanical circulatory support device for high-risk PCI — directly comparable catheter-based platform targeting the same patient population.
• LivaNova: Through the TandemLife acquisition (TandemHeart), LivaNova markets a percutaneous ventricular assist system for short-term mechanical circulatory support, making it a direct competitor to Supira in the HRPCI/CS space.
• FineHeart: French developer of the ICOMS (Implantable Cardiac Output Management System), a catheter-based mechanical circulatory support platform with overlapping ambitions in temporary and durable heart failure support.
• Evaheart Inc. Developer of the EVAHEART2 left ventricular assist system, including a percutaneous next-generation platform aimed at short-term mechanical circulatory support in cardiac surgery and HF patients.

Emerging players

• Procyrion: Developer of Aortix, a percutaneous mechanical circulatory support pump for cardiogenic shock and HF; overlaps with Supira in catheter-based ventricular support but with a different anatomical placement.
• Windmill Cardiovascular Systems: Early-stage developer of a catheter-based mechanical circulatory support device; competes with Supira in the catheter-pump category targeting HRPCI and acute HF patients.
• CorWave: Developer of a unique undulating-membrane LVAD technology with both durable and short-term mechanical circulatory support programs; a thematic peer in the next-generation MCS space.
• Ancora Heart: Developer of the AccuCinch ventricular restoration system for heart failure patients — adjacent mechanical therapy approach targeting a similar interventional cardiology and HF specialist customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/supira-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Supira Medical